Patents by Inventor Changqing RUN

Changqing RUN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240294674
    Abstract: A construction method for and an application of a nucleic acid multimerization-mediated multivalent protein drug and vaccine. Specifically provided is a multimeric complex based on complementary nucleic acid backbones. The complex is a multimer formed by complexing of 3-6 monomers having complementary nucleic acid backbones, wherein each monomer is a polypeptide having a nucleic acid single strand. In the multimer, the nucleic acid single strand of each monomer and the nucleic acid single strands of the other two monomers form double strands by means of base complementation, so as to form complementary nucleic acid backbone structures. Also provided are a pharmaceutical composition containing the multimeric complex, a nucleic acid sequence library used for constructing the multimeric complex, and a method for optimizing complementary nucleic acid backbones.
    Type: Application
    Filed: November 25, 2021
    Publication date: September 5, 2024
    Applicant: ASSEMBLY MEDICINE, LLC.
    Inventors: Fan Yang, James Jeiwen Chou, Liujuan Zhou, Yanbing Wang, Chan Cao, Changqing Run
  • Publication number: 20230024592
    Abstract: The present invention provides a half-life extension drug and a library thereof, and a preparation method and application thereof. Specifically, the present invention provides a drug library, comprising: (a) a drug unit; and (b) n half-life extension units, wherein the drug unit comprises a drug element portion and a first nucleic acid element portion connected to the drug element portion, and each half-life extension unit comprises a half-life extension element portion and a second nucleic acid element portion connected to the half-life extension element portion. Moreover, one first nucleic acid element portion of the drug unit and the second nucleic acid element portion of the at least one half-life extension unit may form a “drug unit-half-life extension unit” complex by forming a complementary base pairing structure, and n is a positive integer greater than or equal to 1.
    Type: Application
    Filed: October 26, 2020
    Publication date: January 26, 2023
    Applicant: ASSEMBLY MEDICINE. LLC
    Inventors: James Jeiwen CHOU, Liqiang PAN, Changqing RUN, Liiujuan ZHOU